Media stories about Marrone Bio Innovations (NASDAQ:MBII) have trended positive on Wednesday, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Marrone Bio Innovations earned a news sentiment score of 0.29 on Accern’s scale. Accern also gave media headlines about the basic materials company an impact score of 44.8573201256602 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Marrone Bio Innovations (NASDAQ MBII) traded down 1.99% during mid-day trading on Wednesday, reaching $0.98. The company had a trading volume of 24,202 shares. The firm’s 50-day moving average price is $1.06 and its 200-day moving average price is $1.20. The stock’s market cap is $30.72 million. Marrone Bio Innovations has a 12 month low of $0.85 and a 12 month high of $2.79.

Marrone Bio Innovations (NASDAQ:MBII) last released its earnings results on Monday, August 14th. The basic materials company reported ($0.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.04). The business had revenue of $6.48 million during the quarter, compared to analysts’ expectations of $6.62 million. Equities research analysts forecast that Marrone Bio Innovations will post ($1.01) EPS for the current fiscal year.

A number of research analysts have recently weighed in on MBII shares. Zacks Investment Research upgraded Marrone Bio Innovations from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Piper Jaffray Companies set a $1.00 price objective on Marrone Bio Innovations and gave the company a “hold” rating in a research report on Saturday, July 22nd. HC Wainwright set a $4.00 price objective on Marrone Bio Innovations and gave the company a “buy” rating in a research report on Tuesday, August 15th. Finally, ValuEngine raised Marrone Bio Innovations from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $2.50.

COPYRIGHT VIOLATION WARNING: “Favorable Press Coverage Somewhat Unlikely to Impact Marrone Bio Innovations (MBII) Share Price” was posted by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.dailypolitical.com/2017/11/01/favorable-press-coverage-somewhat-unlikely-to-impact-marrone-bio-innovations-mbii-share-price.html.

Marrone Bio Innovations Company Profile

Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.

Insider Buying and Selling by Quarter for Marrone Bio Innovations (NASDAQ:MBII)

Receive News & Ratings for Marrone Bio Innovations Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations Inc. and related companies with MarketBeat.com's FREE daily email newsletter.